WEBSITE BSE:544332 NSE: FABCLEAN Inc. Year: 2015 Industry: Engineering - Industrial Equipments My Bucket: Add Stock
Last updated: 10:35
No Notes Added Yet
1. Business Overview
Fabtech Technologies Cleanrooms Ltd. (FABCLEAN) is an Indian engineering company specializing in the design, manufacture, installation, and validation of cleanroom solutions and associated equipment. Cleanrooms are controlled environments with low levels of pollutants such as dust, airborne microbes, aerosol particles, and chemical vapors, essential for industries requiring sterile or particle-free manufacturing conditions. The company's core business model involves providing integrated cleanroom solutions, including modular cleanroom panels, air handling units (AHUs), HEPA filters, pass boxes, laminar air flow units, and other specialized equipment. They make money through project-based contracts for setting up new cleanrooms or upgrading existing facilities, as well as sales of individual cleanroom components and equipment.
2. Key Segments / Revenue Mix
While specific revenue breakdowns are not publicly detailed, FABCLEAN's business primarily revolves around cleanroom projects and related equipment. Its offerings can be broadly categorized by the type of client industry and solution provided:
Pharma & Biotech Cleanrooms: Designing and building controlled environments for drug manufacturing, R&D labs, and biotechnology processes.
Electronics & Semiconductor Cleanrooms: Providing ultra-clean environments for precision manufacturing of electronic components.
Healthcare & Medical Device Cleanrooms: Solutions for hospitals, surgical suites, and medical device production.
Cleanroom Equipment & Components: Sales of individual cleanroom products such as modular walls, ceilings, doors, air filters, and pass-through systems.
Revenue is largely project-driven, with integrated solutions comprising a significant portion.
3. Industry & Positioning
The cleanroom industry is highly specialized, regulated, and capital-intensive, serving critical sectors that demand stringent environmental control. It involves complex engineering, adherence to global regulatory standards (e.g., ISO, US FDA, WHO GMP), and precision manufacturing. FABCLEAN operates as an integrated solutions provider, offering end-to-end services from design to validation. In the Indian context, it positions itself as a key player capable of delivering comprehensive, customized cleanroom solutions, competing with both domestic specialized engineering firms and potentially global players for large-scale projects. The market is fragmented with several regional players, but fewer offer the full spectrum of integrated services.
4. Competitive Advantage (Moat)
FABCLEAN's competitive advantages likely stem from:
Technical Expertise & Experience: A deep understanding of cleanroom technology, regulatory compliance (GMP, ISO), and industry-specific requirements, built over years of project execution.
Integrated Solutions Capability: Ability to provide a complete design-to-validation service, reducing complexity and coordination challenges for clients.
Track Record & Reputation: A proven history of successfully delivering projects, which is crucial for securing new contracts in a trust-based, high-stakes industry.
Customization & Flexibility: Capacity to tailor cleanroom designs and equipment to specific client needs and unique processes.
Switching Costs: Once a cleanroom system is installed and validated, clients face high costs and operational disruption in switching providers for maintenance, upgrades, or expansion, creating a sticky customer base.
5. Growth Drivers
Growth in Pharma & Biotech: The expanding Indian pharmaceutical and biotechnology sectors, driven by R&D, manufacturing capacity expansion, and increasing healthcare spending, directly fuels demand for cleanrooms.
"Make in India" & PLI Schemes: Government initiatives promoting domestic manufacturing in sectors like electronics, medical devices, and pharmaceuticals necessitate new cleanroom infrastructure.
Increased Regulatory Scrutiny: Stricter quality control and compliance standards by regulatory bodies (e.g., US FDA, European Medicines Agency) for manufacturing processes require state-of-the-art cleanroom facilities.
Technological Advancements: Continuous innovation in areas like semiconductors, nanotechnology, and advanced materials requires increasingly sophisticated cleanrooms.
Healthcare Infrastructure Development: Expansion of hospitals, research centers, and diagnostic labs, especially post-pandemic, drives demand for controlled environments.
6. Risks
Project Execution Risk: Delays, cost overruns, and quality issues in complex cleanroom projects can impact profitability and reputation.
Economic Downturns: Cleanroom projects are often capital expenditures, making the company susceptible to economic slowdowns affecting client investment decisions.
Regulatory Changes: Evolving cleanroom standards and compliance requirements can necessitate adaptation and investment, potentially impacting project timelines and costs.
Intense Competition: The presence of both domestic and international players can lead to pricing pressure and margin erosion.
Dependency on Key Sectors: A significant portion of revenue may be tied to the performance and CAPEX cycles of specific industries (e.g., pharma), making it vulnerable to sector-specific downturns.
Raw Material Price Volatility: Fluctuations in prices of materials like steel, aluminum, and specialized components can affect project profitability.
7. Management & Ownership
FABCLEAN is likely a promoter-led company, a common structure in India, where the founding family or individuals hold significant ownership and play a key role in management. In a specialized engineering sector like cleanrooms, the experience and technical expertise of the promoters and senior management are crucial for securing and executing complex projects. Their ability to navigate regulatory landscapes and build long-term client relationships is vital. The ownership structure would typically involve the promoter group holding a substantial stake, ensuring alignment with long-term strategic goals, alongside public shareholders.
8. Outlook
FABCLEAN operates in a critical and growing niche, driven by strong tailwinds from the pharmaceutical, biotechnology, electronics, and healthcare sectors, particularly in India. The increasing emphasis on domestic manufacturing, R&D, and stringent quality control provides a robust demand environment for its specialized cleanroom solutions. Its integrated approach and technical expertise offer a distinct advantage in securing complex projects. However, the business is exposed to typical project execution risks, capital expenditure cycles of client industries, and competitive pressures. Sustained growth will depend on its ability to continually innovate, adhere to evolving global standards, manage project delivery efficiently, and expand its client base while navigating economic uncertainties.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹366 Cr.
Stock P/E 30.1
P/B 3.5
Current Price ₹297.1
Book Value ₹ 84.1
Face Value 10
52W High ₹470
Dividend Yield 0%
52W Low ₹ 203.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 114 | 125 | 97 | 150 | |
| Other Income | 0 | 0 | 1 | 1 | |
| Total Income | 114 | 125 | 98 | 151 | |
| Total Expenditure | 107 | 112 | 89 | 134 | |
| Operating Profit | 6 | 13 | 9 | 17 | |
| Interest | 1 | 1 | 1 | 1 | |
| Depreciation | 1 | 1 | 0 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 5 | 12 | 7 | 16 | |
| Provision for Tax | 1 | 4 | 2 | 4 | |
| Profit After Tax | 4 | 8 | 5 | 12 | |
| Adjustments | -0 | -0 | 0 | 1 | |
| Profit After Adjustments | 4 | 8 | 6 | 13 | |
| Adjusted Earnings Per Share | 4.3 | 9.5 | 6.7 | 10.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 55% | 10% | 0% | 0% |
| Operating Profit CAGR | 89% | 42% | 0% | 0% |
| PAT CAGR | 140% | 44% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -4% | NA% | NA% | NA% |
| ROE Average | 17% | 16% | 14% | 14% |
| ROCE Average | 22% | 21% | 19% | 19% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 38 | 46 | 52 | 94 |
| Minority's Interest | 1 | 1 | 1 | 1 |
| Borrowings | 0 | 0 | 1 | 0 |
| Other Non-Current Liabilities | 1 | 1 | 0 | 1 |
| Total Current Liabilities | 43 | 33 | 35 | 28 |
| Total Liabilities | 82 | 80 | 89 | 124 |
| Fixed Assets | 4 | 4 | 5 | 4 |
| Other Non-Current Assets | 1 | 1 | 2 | 11 |
| Total Current Assets | 77 | 75 | 82 | 109 |
| Total Assets | 82 | 80 | 89 | 124 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 1 | 1 | 2 |
| Cash Flow from Operating Activities | 3 | 8 | 3 | 3 |
| Cash Flow from Investing Activities | -4 | -3 | -2 | -26 |
| Cash Flow from Financing Activities | 1 | -4 | -1 | 24 |
| Net Cash Inflow / Outflow | -0 | 1 | 0 | 1 |
| Closing Cash & Cash Equivalent | 1 | 2 | 2 | 3 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.31 | 9.53 | 6.66 | 10.79 |
| CEPS(Rs) | 5.06 | 10.21 | 7.1 | 10.37 |
| DPS(Rs) | 0 | 0 | 0 | 2 |
| Book NAV/Share(Rs) | 44.96 | 54.49 | 61.77 | 76.63 |
| Core EBITDA Margin(%) | 5.48 | 10.3 | 8.7 | 10.78 |
| EBIT Margin(%) | 5.19 | 10.23 | 8.81 | 10.94 |
| Pre Tax Margin(%) | 4.52 | 9.26 | 7.66 | 10.59 |
| PAT Margin (%) | 3.21 | 6.42 | 5.58 | 8.1 |
| Cash Profit Margin (%) | 3.72 | 6.84 | 6.09 | 8.51 |
| ROA(%) | 4.46 | 9.88 | 6.42 | 11.44 |
| ROE(%) | 9.7 | 19.26 | 11.19 | 16.64 |
| ROCE(%) | 12.8 | 26.21 | 15.8 | 21.5 |
| Receivable days | 165.3 | 147.24 | 188.67 | 127.28 |
| Inventory Days | 46.43 | 40.33 | 53.97 | 42.29 |
| Payable days | 104.5 | 93.16 | 113.17 | 75.61 |
| PER(x) | 0 | 0 | 0 | 31.41 |
| Price/Book(x) | 0 | 0 | 0 | 4.42 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.59 |
| EV/Net Sales(x) | 0.05 | -0.01 | -0.01 | 2.73 |
| EV/Core EBITDA(x) | 0.92 | -0.09 | -0.15 | 24.05 |
| Net Sales Growth(%) | 0 | 9.65 | -21.88 | 54.05 |
| EBIT Growth(%) | 0 | 116.22 | -32.72 | 91.4 |
| PAT Growth(%) | 0 | 119.51 | -32.1 | 123.54 |
| EPS Growth(%) | 0 | 121.17 | -30.1 | 62.05 |
| Debt/Equity(x) | 0.23 | 0.12 | 0.11 | 0.01 |
| Current Ratio(x) | 1.8 | 2.27 | 2.35 | 3.91 |
| Quick Ratio(x) | 1.46 | 1.87 | 1.9 | 3.23 |
| Interest Cover(x) | 7.78 | 10.62 | 7.64 | 30.85 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 68.41 | 68.49 | 68.49 |
| FII | 0.69 | 0 | 0 |
| DII | 11.21 | 8.97 | 5.65 |
| Public | 19.7 | 22.54 | 25.86 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Promoter | 0.84 | 0.84 | 0.84 |
| FII | 0.01 | 0 | 0 |
| DII | 0.14 | 0.11 | 0.07 |
| Public | 0.24 | 0.28 | 0.32 |
| Others | 0 | 0 | 0 |
| Total | 1.23 | 1.23 | 1.23 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.